{Reference Type}: Journal Article
{Title}: Low expression of MEOX2 is associated with poor survival in patients with breast cancer.
{Author}: Wang H;Tang Y;Wang M;Zhao J;Ding C;Yang X;Han P;Liu P;
{Journal}: Biomark Med
{Volume}: 16
{Issue}: 16
{Year}: 11 2022
{Factor}: 2.498
{DOI}: 10.2217/bmm-2022-0468
{Abstract}: Aim: To investigate associations of MEOX2 expression with clinicopathological features and survival of breast cancer patients. Materials & methods: We used a breast cancer tissue microarray for immunohistochemistry. Associations between MEOX2 expression and clinicopathological features were analyzed using the χ-square test. Survival analysis was determined using a Kaplan-Meier curve. Multivariate Cox regression was used to determine associations of MEOX2 expression with overall survival. Results: We found that 74.1% of patients (100/135) had expression of MEOX2 at varying levels. MEOX2 was associated with histological grade and negatively correlated with Ki67 expression. Lower MEOX2 expression was significantly associated with decreased overall survival (p = 0.0011). Conclusion: MEOX2 expression could be a novel diagnostic and prognostic biomarker of breast cancer.<BR>In this study we found that lower expression of the protein MEOX2 was associated with poor overall survival in breast cancer. MEOX2 is an independent prognostic factor for breast cancer patients. It would be a new diagnostic and prognostic biomarker for breast cancer.